RxDoctor Payments Data

Francis Maccedo, MD

Interventional Cardiology · Leesburg, FLNPI 1538379854

Payments from drug & device makers

$33,848in general payments, 2019–2025

Across 123 payments — averaging $275.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$29K
  • Edwards Lifesciences$2K
  • Abbott$1K
  • Baylis Medical Company Inc$993
  • Inari Medical, Inc.$224
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$176
  • plus $675 from 16 others

What the payments were for

  • Grants$22,00065%
  • Travel & lodging$7,51422%
  • Food & beverage$4,13212%
  • Education$2021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,848 in reported general payments places this provider in the 70th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$190,736
Medicare patients
468
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$199,457
EntrestoSacubitril/Valsartan105$111,058
XareltoRivaroxaban42$43,400
BrilintaTicagrelor27$21,048
JardianceEmpagliflozin23$20,714
Flecainide Acetate19$1,763
Metoprolol Succinate118$1,556
Atorvastatin Calcium128$1,504
ClopidogrelClopidogrel Bisulfate130$1,231
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$1,098
Potassium Chloride61$993
Ranolazine ErRanolazine11$966
Amiodarone Hcl26$887
Nifedipine ErNifedipine23$847
Losartan Potassium59$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$199,457147 claims
NovartisEntresto$11$111,058105 claims
Johnson & JohnsonXarelto$123$43,40042 claims
AstraZenecaBrilinta$62$21,04827 claims
Boehringer IngelheimJardiance$20$20,71423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Leesburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →